Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 12069 Views
-
Last post by NHE
-
- 0 Replies
- 1177 Views
-
Last post by NHE
-
- 0 Replies
- 1948 Views
-
Last post by frodo
-
- 0 Replies
- 1247 Views
-
Last post by frodo
-
- 0 Replies
- 2112 Views
-
Last post by NHE
-
- 0 Replies
- 1699 Views
-
Last post by frodo
-
- 0 Replies
- 1313 Views
-
Last post by NHE
-
- 1 Replies
- 1793 Views
-
Last post by frodo
-
- 0 Replies
- 2533 Views
-
Last post by NHE